Show simple item record

dc.contributor.authorDietis, Nikolasen
dc.contributor.authorRowbotham, D. J.en
dc.contributor.authorLambert, D. G.en
dc.creatorDietis, Nikolasen
dc.creatorRowbotham, D. J.en
dc.creatorLambert, D. G.en
dc.date.accessioned2018-06-22T09:52:55Z
dc.date.available2018-06-22T09:52:55Z
dc.date.issued2011
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41563
dc.description.abstractDespite the existence of a family of 3 classical and one non-classical opioid receptor, morphine, acting at the MOP (μ) receptor remains the gold standard for use in cancer pain. The main thrust of opioid development has been to produce highly selective morphine like molecules but these produce side effects (respiratory depression and arrest, constipation, nausea and vomiting, pruritis and tolerance). Tolerance is particularly troublesome as this leads to increased dosing and more side effects. Laboratory experiments suggest that simultaneous targeting of multiple members of the opioid family may be the way forward. For example disruption of DOP (δ) receptor activity reduces morphine tolerance. Rational design and evaluation of non-selective opioids might offer good quality analgesia, reduced side effects and an alternative to morphine. © 2011 Elsevier Ltd.en
dc.language.isoengen
dc.sourceTrends in Anaesthesia and Critical Careen
dc.subjectCancer painen
dc.subjectMorphineen
dc.subjectOpioidsen
dc.titleControlling cancer pain: Is morphine the best we can do?en
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.tacc.2011.08.003
dc.description.volume1
dc.description.issue5-6
dc.description.startingpage227
dc.description.endingpage229
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidDietis, Nikolas [0000-0002-8365-3837]


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record